Xilio Therapeutics, Inc. (XLO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xilio Therapeutics, Inc. on June 17, 2024, regarding events occurring on June 13, 2024. The filing details the results of the Company's 2024 Annual Meeting of Stockholders. Xilio Therapeutics is an emerging growth company incorporated in Delaware, with its principal executive offices in Waltham, Massachusetts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
The primary material event reported is the outcome of the stockholder votes at the annual meeting:
- Election of Directors: Stockholders elected Paul J. Clancy and Christina Rossi as Class III directors for three-year terms expiring in 2027.
- Director Vote Results:
- Paul J. Clancy: 18,450,957 votes For; 1,087,467 votes Withheld; 6,783,293 Broker Non-Votes.
- Christina Rossi: 18,451,038 votes For; 1,087,386 votes Withheld; 6,783,293 Broker Non-Votes.
- Ratification of Auditors: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Auditor Vote Results: 26,199,617 votes For; 101,371 votes Against; 20,729 votes Abstaining.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, contingencies, or unusual items. The document is limited to the procedural results of the annual meeting.
Key Facts for Investor Verification
- Confirmation that Paul J. Clancy and Christina Rossi have officially assumed their roles as Class III directors.
- Verification of the high level of broker non-votes (approximately 6.78 million) relative to votes cast for director elections.
- Confirmation that Ernst & Young LLP will serve as the auditor for the fiscal year ending December 31, 2024.
- Review of the Company's most recent 10-K or 10-Q filings for financial data, as this 8-K contains no financial metrics.